Incyte Corporation (INCY)
Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma
The FDA approves INCY's Monjuvi in combination with rituximab and lenalidomide for relapsed/refractory follicular lymphoma, its second approved indication.
Incyte Stock Rises on QIAGEN Deal to Advance Blood Cancer Diagnostics
INCY jumps 5.1% on a global QIAGEN deal to develop a companion diagnostic for its mutCALR-targeting cancer therapy.
Why Is Incyte (INCY) Up 3.6% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte Gets FDA Approval for Zynyz in New Cancer Indication
The FDA approves INCY's Zynyz both as monotherapy and in combination with chemotherapy for treating advanced anal cancer.
Incyte Corporation (INCY) Q1 2025 Earnings Call Transcript
Incyte Corporation (NASDAQ:INCY ) Q1 2025 Earnings Conference Call April 29, 2025 8:00 AM ET Company Participants Greg Shertzer - Director of Investor Relations Herve Hoppenot - Chief Executive Officer Pablo Cagnoni - President, Head of Research and Development Christiana Stamoulis - Executive Vice President and Chief Financial Officer Matteo Trotta - EVP, Head of U.S. Dermatology Mohamed Issa - EVP, Head of U.S. Oncology Steven Stein - Chief Medical Officer Conference Call Participants Michael Schmidt - Guggenheim David Lebowitz - Citi Andrew Barrons - Leerink Partners Tazeen Ahmad - Bank of America Jessica Fye - JPMorgan Chase Marc Frahm - TD Cowen Vikram Purohit - Morgan Stanley Ash Verma - UBS James Shin - Deutsche Bank Salim Syed - Mizuho Securities Gavin Clark-Gartner - Evercore ISI Jay Olson - Oppenheimer Operator Greetings, and welcome to the Incyte's First Quarter 2025 Earnings Conference and Webcast. At this time, all participants are in a listen-only mode.
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Here's What Key Metrics Tell Us About Incyte (INCY) Q1 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Incyte (INCY) Q1 Earnings and Revenues Top Estimates
Incyte (INCY) came out with quarterly earnings of $1.16 per share, beating the Zacks Consensus Estimate of $1.01 per share. This compares to earnings of $0.64 per share a year ago.
Incyte Gears Up to Report Q1 Earnings: Here's What You Should Know
INCY is likely to beat Q1 earnings estimates, primarily driven by increased U.S. sales and royalties from Novartis on ex-U.S. sales of its lead drug, Jakafi.
Incyte (INCY) Reports Next Week: Wall Street Expects Earnings Growth
Incyte (INCY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Incyte Stock Was Tanking This Week
A less-than-encouraging clinical trial for an investigative medicine was the news driving down Incyte (INCY 2.23%) stock over the past few days. The gloom this produced was pushing the biotech's share price down by nearly 11% week to date as of Friday before market open.
INCY Stock Down on Disappointing Skin Disease Study Data
Incyte declines as data from phase III studies on povorcitinib, for the treatment of hidradenitis suppurativa, fail to meet investor expectations.
